Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Roquefort Investments PLC ( (GB:ROQ) ) has issued an announcement.
Roquefort Therapeutics PLC has announced the issuance of 2,466,547 new ordinary shares to settle amounts owed to a former employee. These shares will be admitted to trading on the London Stock Exchange’s Main Market, increasing the company’s total issued share capital to 157,444,030 ordinary shares. This move reflects the company’s ongoing financial management and strategic positioning in the biotech industry, potentially impacting shareholder calculations under the FCA’s Disclosure and Transparency Rules.
More about Roquefort Investments PLC
Roquefort Therapeutics PLC is a biotech company listed on the London Stock Exchange, focusing on developing first-in-class medicines in the high-value and high-growth immunology and oncology markets. The company’s portfolio includes five novel, patent-protected pre-clinical anti-cancer and immunology assets.
Average Trading Volume: 1,740,886
Technical Sentiment Signal: Sell
Current Market Cap: £2.79M
For detailed information about ROQ stock, go to TipRanks’ Stock Analysis page.